智通财经网·2026-01-27 01:53Core Viewpoint - The medical and healthcare industry in China is expected to experience stable and continuous growth driven by innovation and supportive policies, leading to a return to a market pricing system based on clinical value and demand [1] Group 1: Investment Trends - The pharmaceutical industry is projected to maintain an overweight status, with key investment lines focusing on innovation-driven and internationalization strategies, self-sufficiency in core components, and benefits from new policies [1] - The report predicts that 64 out of 76 covered pharmaceutical companies will achieve year-on-year positive growth or remain stable in their performance for Q4 2025/H2, while 12 companies may face negative growth or losses [1] - The acceleration of innovation in pharmaceutical and medical enterprises is expected to translate into performance growth, driven by external business development (BD) and commercialization [1] Group 2: Innovation and Licensing - 2025 is anticipated to be a significant year for the licensing of Chinese innovative drugs, with upfront payments and potential milestones contributing to substantial growth in the financial reports of various pharmaceutical companies [2] - Many biotech firms are expected to realize the global value of their core products through licensing, which will enhance their financial performance and support new rounds of research and development investments [2] - The demand for asset acquisition remains strong among multinational pharmaceutical companies, indicating a sustainable wave of outbound licensing for Chinese innovative drugs [2] Group 3: Industry Chain Insights - The geopolitical influences are diminishing, and the funding structure for domestic pharmaceutical companies is improving, leading to signs of recovery in biopharmaceutical investment and financing [3] - The early-stage research demand for large molecule antibodies and ADCs is recovering, with expectations for increased IPO activity in Hong Kong and a rebound in clinical CRO segments in 2026 [3] - Domestic CDMO companies are expected to stabilize and recover in new order signings, driven by the ongoing demand for new molecules such as ADCs and peptides [3] Group 4: Medical Industry Chain - The medical industry chain is showing signs of recovery, with expectations for continued growth in Q4 2025 and into 2026, particularly in sectors like medical devices, IVD, and OTC traditional Chinese medicine [4][5] - Three main investment lines for 2026 include an improved domestic payment environment for innovative drugs and devices, a harvest period for overseas expansion, and the emergence of new business models such as brain-computer interfaces and AI in healthcare [4][5]